PARG-deficient tumor cells have an increased dependence on EXO1/FEN1-mediated DNA repair

Targeting poly(ADP-ribose) glycohydrolase (PARG) is currently explored as a therapeutic approach to treat various cancer types, but we have a poor understanding of the specific genetic vulnerabilities that would make cancer cells susceptible to such a tailored therapy. Moreover, the identification o...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:The EMBO journal Ročník 43; číslo 6; s. 1015 - 1042
Hlavní autoři: Andronikou, Christina, Burdova, Kamila, Dibitetto, Diego, Lieftink, Cor, Malzer, Elke, Kuiken, Hendrik J, Gogola, Ewa, Ray Chaudhuri, Arnab, Beijersbergen, Roderick L, Hanzlikova, Hana, Jonkers, Jos, Rottenberg, Sven
Médium: Journal Article
Jazyk:angličtina
Vydáno: London Nature Publishing Group UK 15.03.2024
Témata:
Biomedical and Life Sciences
DNA Damage
DNA Repair
DNA Repair Enzymes - genetics
EMBO03
EMBO13
EMBO31
Exodeoxyribonucleases - genetics
Flap Endonucleases - genetics
Flap Endonucleases - metabolism
Flap Endonucleases - therapeutic use
Glycoside Hydrolases - genetics
Glycoside Hydrolases - metabolism
Humans
Life Sciences
Neoplasms - drug therapy
Neoplasms - genetics
Poly(ADP-ribose) Polymerase Inhibitors - pharmacology
Tumor Suppressor Protein p53 - genetics
Tumor Suppressor Protein p53 - metabolism
FEN1
PARG
BRCA2
EXO1
DNA Repair
ISSN:1460-2075, 0261-4189, 1460-2075
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Targeting poly(ADP-ribose) glycohydrolase (PARG) is currently explored as a therapeutic approach to treat various cancer types, but we have a poor understanding of the specific genetic vulnerabilities that would make cancer cells susceptible to such a tailored therapy. Moreover, the identification of such vulnerabilities is of interest for targeting BRCA2;p53-deficient tumors that have acquired resistance to poly(ADP-ribose) polymerase inhibitors (PARPi) through loss of PARG expression. Here, by performing whole-genome CRISPR/Cas9 drop-out screens, we identify various genes involved in DNA repair to be essential for the survival of PARG;BRCA2;p53-deficient cells. In particular, our findings reveal EXO1 and FEN1 as major synthetic lethal interactors of PARG loss. We provide evidence for compromised replication fork progression, DNA single-strand break repair, and Okazaki fragment processing in PARG;BRCA2;p53-deficient cells, alterations that exacerbate the effects of EXO1/FEN1 inhibition and become lethal in this context. Since this sensitivity is dependent on BRCA2 defects, we propose to target EXO1/FEN1 in PARPi-resistant tumors that have lost PARG activity. Moreover, EXO1/FEN1 targeting may be a useful strategy for enhancing the effect of PARG inhibitors in homologous recombination-deficient tumors. Synopsis Targeting poly(ADP-ribose) glycohydrolase (PARG) is being explored as anti-cancer therapeutic strategy, and PARG loss may also contribute to resistance to PARP inhibitor (PARPi) treatment. This study provides insights into specific vulnerabilities that can render homologous-recombination (HR)-deficient tumors susceptible to the loss of PARG activity. Impaired de-PARylation in PARG-deficient cells affects the repair of single-strand breaks (SSBs) and processing of unligated Okazaki fragments. Genome-wide CRISPR/Cas9 screens reveal EXO1 and FEN1 as critical factors in cells deficient for PARG and BRCA2. Inhibition of EXO1/FEN1 in PARG;BRCA2-deficient cells results in unresolved Okazaki fragments, which persist as single-strand DNA (ssDNA) gaps. Persistent ssDNA gaps become specifically lethal to HR-deficient cells when converted into double-strand breaks (DSBs) upon replication. Genome-wide loss-of-function screens reveal DNA repair genes essential in HR-defective cells lacking PARG, suggesting ways for therapeutically exploiting PARG inhibitors and targeting PARPi-resistant tumors.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1460-2075
0261-4189
1460-2075
DOI:10.1038/s44318-024-00043-2